Fasting-mimicking diet

Studies of fasting-mimicking diet in people

36 studies gave fasting-mimicking diet to people and measured what changed

What changedDesignPeopleSource

down: Decreases glucose4.7 mmol/L to 4.0 mmol/L

down: Decreases IGF-123 nmol/L to 17.9 nmol/L

up: Increases ketonenear zero to median 1.86 mmol/L

Trialtwo cycles of a 4-day FMD separated by 3 weeks of regular diet9 peopleHealthy volunteersNutrients, Aug 3, 2026

down: Decreases left ventricular massmean difference, -5.47 g

up: Improves early-to-late peak filling ratiomean difference, 0.27

up: Improves mitral annular early peak velocitymean difference, 0.84 cm/sec

Randomized trial6 months82 peopleBothmean age, 62.9 years ± 8.5Older adults; in individuals with type 2 diabetesRadiology. Cardiothoracic imaging, Jul 30, 2026

up: Improves clinical response69.2% FMD versus 43.8% control

up: Improves clinical remission64.6% FMD versus 37.5% control

down: Decreases calprotectin−22.0% versus 8.0%

Randomized trialthree months97 peoplemedian age 45.0 years (IQR 35.0 to 55.0)Patients with mild-to-moderate Crohn's diseaseNature medicine, Jan 13, 2026

down: Decreases body weight

down: Decreases fasting glucose

down: Decreases HOMA-IR

Randomized trial8 days30 people83.3% were femalemean age of 49.1 ± 11.8 yearsParticipants recruited from the San Antonio, Texas USA communityGeroScience, Dec 11, 2025

no change: Has no effect on quality of lifeunadjusted mean difference −0.04, 95% CI −0.10 to 0.03

Randomized trialone year92 peoplePatients with type 2 diabetesBMC primary care, Nov 10, 2025

down: Decreases IGF-1

down: Decreases body mass-2.04 ± 0.42 kg [-2.86, -1.21 kg]

down: Decreases fat mass

Trialthree cycles of the 5-day FMD30 peoplefemale genderaged ≥ 18 yearsPatients with histologically confirmed invasive breast cancer scheduled to receive chemotherapyBreast cancer research and treatment, Jul 25, 2025

down: Decreases abdominal visceral adipose tissue-37.9 cm2 (95 % CI -54.7, to -21.0)

down: Decreases abdominal subcutaneous adipose tissue-20.9 cm2 (95 %CI -34.5 to -7.3)

no change: Has no effect on abdominal muscle area-1.6 cm2 (95 % CI -4.6 to 1.4)

Randomized trial12 months89 peoplePatient cohortsNutrition, metabolism, and cardiovascular diseases : NMCD, Apr 30, 2025

down: Decreases C-reactive protein-0.20 ± 0.30 mg/l vs -0.11 ± 0.52 mg/l (p = 0.632)

Randomized trial3 months19 peoplePost-non-surgical periodontal therapyJournal of dentistry, Feb 19, 2025

down: Decreases proton density fat fraction-2.8 %, 95 % CI -4.7 to -0.8

down: Decreases iron content corrected T1-29.9 ms, 95 % CI -51.8 to -8.0

Randomized trial12 months89 peopleType 2 diabetesClinical nutrition (Edinburgh, Scotland), Feb 18, 2025

up: Improves chemosensory function

down: Decreases hyposmia5.9-fold decrease, from 38.1% to 6.4%

Randomized trial5 consecutive days each month for 6 months102 people58 females out of 113 enrolled53.1 ± 12.3 yearsCaucasian adults with BMI ≥25Cell reports. Medicine, Feb 18, 2025

down: Decreases myocardial triglyceride content-0.235 % MTGC, p = 0.027

Randomized trial12-month100 peopleType 2 diabetesNutrition, metabolism, and cardiovascular diseases : NMCD, Jan 9, 2025

down: Decreases body weight

up: Increases L-glutamine

Treated cohortbioRxiv (Cold Spring Harbor Laboratory), Dec 30, 2024

down: Decreases grade III vomiting

down: Lowers the risk of neutropenia

down: Decreases IGF-1

Randomized trial3 days before to and on the day of each cycle of chemotherapy44 peopleaged between 35 and 68 yearsRecently diagnosed HER-2 negative BC patientsFrontiers in nutrition, Dec 4, 2024

down: Decreases proteinuria

up: Improves endothelial function

Trial3 monthsIn patients with chronic kidney diseaseScience translational medicine, Oct 30, 2024

no change: Has no effect on diet quality

up: Increases physical activity34.6 to 38.5 h/wk vs 34.9 to 29.0 h/wk, p = 0.03

Randomized trialone year92 peopleaged > 18 years and < 75 yearsPatients diagnosed with type 2 diabetes with BMI ≥ 27 kg/m2BMC primary care, May 2, 2024

down: Decreases medication effect score−0.3 (95% CI −0.4, −0.2)

down: Decreases HbA1c−3.2 mmol/mol (95% CI −8.0, −2.0)

up: Improves glycaemic management53% vs 8%

Randomized trial12 months100 people>18 years and <75 yearsIndividuals with type 2 diabetes and BMI ≥27 kg/m2Diabetologia, Mar 28, 2024

down: Decreases biological age-2.5 years

down: Decreases insulin resistance1.473 ± 0.85 to 1.209 ± 0.99

down: Decreases hepatic fat

Randomized trialthree cycles of this 5-day FMD100 people18 to 70 years of ageGenerally healthy adult volunteers without a diagnosed medical condition in the previous 6 monthsNature communications, Feb 20, 2024

down: Decreases reactive hyperemia index−0.4 in FMD vs not in MD

down: Decreases PULS cardiac test scoreFMD: −1.5 (p = 0.0224) vs. MD: −2.3 (p = 0.0390)

Randomized trial4 months84 peopleThe FMD arm included 32 females versus 20 in the MD armover the age of 35 to 75 yearsSubjects of both sexes over the age of 35 to 75 yearsnpj metabolic health and disease, Dec 13, 2023

up: Extends lifespan overall survivalHR 0.40, 95% CI 0.19-0.86

Treated cohortPatient cohortsInternational journal of cancer, Aug 24, 2023

up: Increases skin hydration25.1% vs 8.52%

Randomized trial71 days45 peoplefemale participantsranging in age from 35 to 60 years oldFemale participants in good general health and social well-being with mild to moderate scores for parameters on the global faceJournal of clinical medicine, Feb 21, 2023

up: Improves quality of lifep < 0.05

up: Improves sleep qualityp < 0.05

down: Decreases body weightconsiderably reduced

Randomized trialtwo months62 peopleMen50-60 years oldMidlife adults; obesity hypoventilation syndromeJournal of complementary & integrative medicine, Sep 30, 2022

no change: Has no effect on albumin-to-creatinine ratio110.3 (99.2, 121.5) mg/g, P = 0.45

down: Decreases albumin-to-creatinine ratio−30.3 (−35.7, −24.9) mg/g, P ≤ 0.05

down: Decreases HOMA-IR−3.8 (−5.6, −2.0), P ≤ 0.05

Randomized trial6 diet cycles41 people50 to 75 yearsPatients with type 2 diabetes with good glycemic and blood pressure control, optimized treatment, and increased ACRThe Journal of clinical endocrinology and metabolism, Jun 7, 2022

down: Decreases body weight-3.79 kg (95% CI 1.97–5.61 kg)

down: Decreases abdominal circumference-4.57 cm

down: Decreases systolic blood pressure-9.52 mmHg

Trial3 cycles of a 4-day diet35 peoplemenProspective group of men with prostate cancer treated in a community oncology settingProstate cancer and prostatic diseases, Mar 21, 2022

down: Decreases trimethylamine N-oxide

down: Decreases body weight

down: Decreases IGF-1-37 ± 8 ng/mL

Trial5 days44 peopleGenerally healthy omnivorous volunteersNutrients, Mar 5, 2022

down: Decreases body mass-2.6 kg

no change: Has no effect on muscle strength

no change: Has no effect on muscle volume

Randomized trial1 cycle24 peopleMenEuropean journal of applied physiology, Jan 16, 2022

down: Decreases albumin-to-creatinine ratio-30.3 mg/g (95% CI -35.7, -24.9 mg/g; P≤0.05)

down: Decreases HOMA-IR-3.8 (95% CI -5.6, -2.0; P≤0.05)

Randomized trialsix months40 peopleIn patients with microalbuminuriamedRxiv, Dec 5, 2021

down: Decreases glucose

down: Decreases regulatory T cells

Trial5-day101 peoplePatient cohortsCancer discovery, Nov 17, 2021

no change: Has no effect on body weight

down: Decreases fat mass

down: Decreases IGF-1

Trial2 to 21 FMD cycles (average: 6.3 cycles per patient)90 people86% were females50.4 ± 8 years (range 19–72)Cancer patients with solid or hematological tumors undergoing active treatmentCancers, Aug 9, 2021

no change: Has no effect on body weight-2.29 (1.95) kg vs -1.13 (2.27) kg, p = 0.06

down: Decreases fat mass

up: Improves muscle mass

Randomized trial2 months60 peopleWomen18-55 yearsMetabolically healthy women with obesityObesity surgery, Jan 9, 2021

down: Decreases HbA1c6.47 ± 0.51% vs 7.50 ± 0.50%

down: Decreases body mass index

up: Increases high-density lipoprotein cholesterol2.28 ± 0.50 vs 1.42 ± 0.27 mmol/L

Randomized trial4-month115 people18–65 yearsPatients with type 2 diabetes and BMI ≥ 28 kg/m2Oxidative medicine and cellular longevity, Dec 5, 2020

up: Improves physical function

down: Decreases symptoms

Randomized trial4-day131 peoplewomenWomen with HER2-negative breast cancerBreast cancer research and treatment, Nov 11, 2020

no change: Has no effect on toxicity

up: Increases radiologically complete or partial responseOR 3.168, P = 0.039

up: Increases pathological responseOR 4.109, P = 0.016

Randomized trial3 days prior to and during neoadjuvant chemotherapy131 peopleWomenNeoadjuvant chemotherapyNature communications, Jun 23, 2020

up: Improves psychological quality of life

down: Decreases body mass index

Randomized trial20 peopleIn patients with depression undergoing functional therapyJournal of clinical psychology, May 11, 2020

no change: Has no effect on patient-reported outcomes

Randomized trial24 or 48 weeks90 peopleIntention-to-treat analysisMultiple sclerosis and related disorders, May 6, 2020

down: Decreases body weight

down: Decreases blood pressure-4.5 ± 6.0 mmHg

down: Decreases IGF-1-21.7 ± 46.2 ng/ml

Randomized trial3 months100 people18 to 70 years of ageGenerally healthy adult volunteersScience translational medicine, Feb 15, 2017

down: Decreases fasting blood glucose-5.9 ± 2.1%

down: Decreases IGF-I~-15%

down: Decreases body weight-3.1 ± 0.3%

Randomized trial3 months19 people18–70 years of ageGenerally healthy adultsCell metabolism, Jun 18, 2015